<DOC>
	<DOC>NCT00408785</DOC>
	<brief_summary>This is a Multicenter, double-blind, randomized, placebo-controlled, parallel-group comparative study to confirm the efficacy and safety of BOTOX 20 units single injection for the Chinese patients with glabellar lines. The subjects will receive a single intramuscular treatment consisting of 5 injections of either BOTOX? 20U or placebo.</brief_summary>
	<brief_title>A Study Of BOTOX For The Treatment Of Glabellar Lines</brief_title>
	<detailed_description />
	<mesh_term>Botulinum Toxins, Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Inclusion criteria: Male and female adult with Glabellar lines of at least moderate severity at maximum frown by investigator's assessment. Exclusion criteria: Patients with systemic nerve conduction junction disorder or patients with infection or other skin disease/surgery at injection sites will not be eligible. Patient with severe complications related to heart, kidney, liver disease or respiratory system will not be eligible.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Botulinum Toxin Type A</keyword>
	<keyword>safety</keyword>
	<keyword>efficacy</keyword>
	<keyword>glabellar lines</keyword>
</DOC>